LCN2 acts as an oncogene that promotes the progression of breast cancer [13] as well as, oral squamous cell carcinoma [38], myeloproliferative neoplasm [39], skin squamous cell carcinoma [40], gastric carcinoma [41], esophageal squamous cell carcinoma [42], thyroid cancer [43], and prostate cancer [44]. Here, LCN2 is linked to myeloproliferative neoplasm.